December 17, 2018 09:54 AM EST
Deals
Pharma

No­vo Nordisk grabs a $486M buy­out op­tion on an an­ti-apoC3 an­ti­body for its car­dio R&D group

John Carroll

Editor & Founder

A cou­ple of months af­ter re­struc­tur­ing its R&D op­er­a­tions, No­vo Nordisk has whipped up a $486 op­tion deal to buy out Stat­en Biotech­nol­o­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times